Host Inflammatory Response in Viral Lower Respiratory Tract Infections: Friend or Foe?

Author:

Moir Hannah1

Affiliation:

1. EMJ, London, UK

Abstract

Viral lower respiratory tract infections (LRTI) are a leading cause of hospitalizations and death worldwide, placing significant pressure on healthcare systems. In this article, two pulmonary critical care specialists explored the prevalence and global burden of viral LRTIs, focusing on recent advancements in understanding the role of dysregulated host immune response and hyper-inflammation. Specifically, they focused on the relevance of alarmin cytokines and their association with adverse patient outcomes. This article reviews the presentations delivered during an industry theater session that took place at the American Thoracic Society (ATS) 2023 International Conference, held in person in Washington, D.C., USA, in May 2023. The primary objective of this session was to provide a comprehensive overview of the impact and burden imposed by severe viral LRTIs. Pratik Sinha, an Assistant Professor in Anesthesiology at Washington University in St. Louis, Missouri, USA, provided valuable insights into the drivers behind the progression of viral LRTIs, which result in significant mortality and morbidity, imposing a considerable clinical burden with unmet needs. Nuala Meyer, an Associate Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, USA, shed light on the dysregulated host immune response and hyper-inflammation triggered by viral infections, which serve as key drivers of disease progression and severe patient outcomes. Sinha also discussed the potential role of alarmin cytokines, particularly IL-33, in influencing the severity and progression of respiratory viral infection. These cytokines may also serve as pleiotropic regulators of the host immune response to viral LRTIs.

Publisher

European Medical Group

Reference52 articles.

1. Centers for Disease Control and Prevention (CDC). 2021–2022 estimated flu illnesses, medical visits, hospitalizations, and deaths prevented by flu vaccination. 2022. Available at: https://www.cdc.gov/flu/about/burden-averted/2021-2022.htm#:~:text=Based%20on%20the%202021-2022%20flu%20disease%20burden%20estimates,and%201%2C000%20deaths%20were%20prevented%20by%20flu%20vaccination. Last accessed: 22 May 2023.

2. Centers for Disease Control and Prevention (CDC). Estimated COVID-19 burden. 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html. Last accessed: 22 May 2023.

3. Centers for Disease Control and Prevention (CDC). 2022-2023 U.S. flu season: preliminary in-season burden estimates. 2023. Available at: https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm. Last accessed: 16 June 2023.

4. European Centre for Disease Prevention and Control (ECDC). Survey on the implementation of integrated surveillance of respiratory viruses with pandemic potential. 2022. Available at: https://www.ecdc.europa.eu/en/news-events/risk-severe-pressure-healthcare-systems-due-rsv-flu-and-covid-19-co-circulation. Last accessed: 22 May 2023.

5. World Health Organization (WHO). The top 10 causes of death. 2020. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Last accessed: 22 May 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3